Early detection of oesophageal cancer improves outcomes, however the optimal strategy for identifying patients at increased risk from the pre-cancerous lesion Barrett's oesophagus (BE) is not clear.
The BEST3 trial is evaluating whether systematic, non-endoscopic investigation of patients on long-term medication for heartburn and acid reflux symptoms is an effective triage test to increase the diagnosis of BE without unduly burdening the clinical service.
The multi-site cluster-randomised controlled trial will evaluate the ability of the CytospongeTM-TFF3 test to identify BE among patients who do not meet guidelines for urgent referral. The study will aim to recruit over 13,000 patients in 120 practices.
The BEST3 study is jointly sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. If you would like more information, please contact email@example.com